Blau Syndrome: Key Insights into a Unique Autoinflammatory Disorder
Anand Kishore Morampudi *
Vikas Institute of Pharmaceutical Sciences, Rajahmundry, India.
Sarada Akula *
Vikas Institute of Pharmaceutical Sciences, Rajahmundry, India.
Naveen Morampudi
Vikas Institute of Pharmaceutical Sciences, Rajahmundry, India.
Sai Swapna Tirumalasetty
Vikas Institute of Pharmaceutical Sciences, Rajahmundry, India.
*Author to whom correspondence should be addressed.
Abstract
Blau syndrome is one of the sporadic auto inflammatory disorders recapitulating early-onset granulomatous inflammation of the skin, joints, and eyes. This hereditary condition is caused by a mutation in the NOD2/CARD15 gene, leading to an imbalance of the innate immune response. An early age of onset characterizes the disease known as Blau syndrome, specifically prevailing before age 4 years. Blau syndrome is characterized by a clinical triad that includes granulomatous dermatitis, symmetric polyarthritis, and recurrent uveitis. Skin involvement consists of small, brownish papules or small plaques. The major joints involved in the wrists, ankles, and hands are affected by arthritis, which can be deformed unless treated. Uveitis may also be severe and may lead to blindness in some cases if left untreated. Diagnosis typically requires a combination of clinical presentation, histopathology, and DNA analysis. Histo-pathological examination usually reveals non-caseating granulomas in skin biopsies. A genetic study showing NOD2 mutations confirms the diagnosis and also differentiates Blau syndrome from other granulomatous conditions. Treatment for Blau syndrome focuses on reducing inflammation and preventing organ damage. Corticosteroids are usually the first line of treatment, but more problematic cases require immunosuppressive/immunomodulatory agents and biological especially TNF-α inhibitors and welfare with these medicines unequivocally offers good prospects. Ongoing follow-up with an ophthalmologist is hence of importance to monitor progression and ensure the adequately timely management of ocular involvement. Even after the recent understanding of its genetic basis and many more pathophysiological mechanisms that lead to Blau syndrome, further research is needed to form targeted treatments to improve long-term outcomes for affected individuals. Awareness about this very rare auto inflammatory disorder must be raised among health professionals at large for its early diagnosis and proper management.
Keywords: Blau syndrome, auto inflammatory disorder, immunosuppressive, granulomatous